UroGen Pharma (URGN) Tops Q2 EPS by 14c

UroGen Pharma (NASDAQ: URGN) reported Q2 EPS of ($1.44), $0.14 better than the analyst estimate of ($1.58). Revenue for the quarter came in at $372 thousand versus the consensus estimate of $260 thousand.

“The second quarter of 2020 has proved to be the most transformational time for UroGen, marked by the U.S. Food and Drug Administration approval of Jelmyto for patients with low-grade upper tract urothelial cancer and our successful transition to a commercial-stage company. Despite global challenges and uncertainty as a result of the ongoing COVID-19 pandemic, the innovative solutions developed by our team have led to strong launch execution; a testament to our commitment to advancing this important medicine for patients in need of better options,” said Liz Barrett, President and Chief Executive Officer of UroGen. “In addition to continuing our commercialization efforts of Jelmyto, we are on track to start our planned Phase 3 pivotal study of UGN-102 in patients with low-grade intermediate risk non-muscle invasive bladder cancer by the end of this year.”

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• NextPlat Corp (NXPL) Reports Q2 Loss of $0.05
• Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS